» Articles » PMID: 24957265

IL-9 and Its Receptor Are Predominantly Involved in the Pathogenesis of UC

Overview
Journal Gut
Specialty Gastroenterology
Date 2014 Jun 25
PMID 24957265
Citations 85
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Several pathogenic roles attributed over the past two decades to either T helper (Th)1 or Th2 cells are increasingly becoming associated with interleukin (IL)-17 and most recently IL-9 signalling. However, the implication of IL-9 in IBD has not been addressed so far.

Design: We investigated the expression of IL-9 and IL-9R by using peripheral blood, biopsies and surgical samples. We addressed the functional role of IL-9 signalling by analysis of downstream effector proteins. Using Caco-2 cell monolayers we followed the effect of IL-9 on wound healing.

Results: IL-9 mRNA expression was significantly increased in inflamed samples from patients with UC as compared with controls. CD3(+) T cells were major IL-9-expressing cells and some polymorphonuclear leucocytes (PMN) also expressed IL-9. IL-9 was co-localised with the key Th9 transcription factors interferon regulatory factor 4 and PU.1. Systemically, IL-9 was abundantly produced by activated peripheral blood lymphocytes, whereas its receptor was overexpressed on gut resident and circulating PMN. IL-9 stimulation of the latter induced IL-8 production in a dose-dependent manner and rendered PMN resistant to apoptosis suggesting a functional role for IL-9R signalling in the propagation of gut inflammation. Furthermore, IL-9R was overexpressed on gut epithelial cells and IL-9 induced STAT5 activation in these cells. Moreover, IL-9 inhibited the growth of Caco-2 epithelial cell monolayers in wound healing experiments.

Conclusions: Our results provide evidence that IL-9 is predominantly involved in the pathogenesis of UC suggesting that targeting IL-9 might become a therapeutic option for patients with UC.

Citing Articles

The role of efferocytosis in inflammatory bowel disease.

Liu Y, Li Z, Han Y, Wang Q Front Immunol. 2025; 16:1524058.

PMID: 40040696 PMC: 11876057. DOI: 10.3389/fimmu.2025.1524058.


Quercetin alleviates ulcerative colitis through inhibiting CXCL8-CXCR1/2 axis: a network and transcriptome analysis.

Jiang Z, Yan M, Qin Y, Liu Z, Duan Y, Wang Y Front Pharmacol. 2024; 15:1485255.

PMID: 39717557 PMC: 11663639. DOI: 10.3389/fphar.2024.1485255.


Th9 and Th17 Cells in Human Ulcerative Colitis-Associated Dysplastic Lesions.

Cui G, Yuan A, Sorbye S, Florholmen J Clin Med Insights Oncol. 2024; 18:11795549241301358.

PMID: 39651422 PMC: 11624539. DOI: 10.1177/11795549241301358.


Fungal influence on immune cells and inflammatory responses in the tumor microenvironment (Review).

Zhang J, Feng Y, Li D, Shi D Oncol Lett. 2024; 29(1):50.

PMID: 39564373 PMC: 11574707. DOI: 10.3892/ol.2024.14796.


Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD.

Bamias G, Menghini P, Pizarro T, Cominelli F Gut. 2024; 74(4):652-668.

PMID: 39266053 PMC: 11885054. DOI: 10.1136/gutjnl-2024-332504.